GeNOsys, Inc.

CIK:0001145328|SEC Filings

Earnings Per Share	3 Months Ended
Aug. 31, 2011
Earnings Per Share
Earnings Per Share [Text Block]	(7) Basic and Diluted Net Loss per Common Share Both basic and diluted net loss per share for the periods ending August 31, 2011 and 2010 are based on the net operating loss for the period divided by the weighted average number of common shares outstanding for the period. The Company’s common stock equivalents at period end were anti-dilutive and therefore excluded from the computation.

Earnings Per Share

3 Months Ended

Aug. 31, 2011

(7) Basic and Diluted Net Loss per Common Share

Both basic and diluted net loss per share for the periods ending August 31, 2011 and 2010 are based on the net operating loss for the period divided by the weighted average number of common shares outstanding for the period. The Company’s common stock equivalents at period end were anti-dilutive and therefore excluded from the computation.

GENOSYS, INC. (A Development Stage Company) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended		75 Months Ended
	Aug. 31, 2011	Aug. 31, 2010	Aug. 31, 2011
Cash flows from operating activities:
Net loss	$ (868,804)	$ (1,107,194)	$ (7,255,488)
Gain on disposal of discontinued operations	0	0	(71,253)
Loss from discontinued operations	0	0	2,131
Loss from continuing operations	(868,804)	(1,107,194)	(7,324,610)
Depreciation and amortization expense	39,292	35,456	249,195
Loss on disposal of property and equipment	0	6,140	6,554
Stock-based compensation	52,885	228,448	1,076,298
Stock issued for services	99,499	14,000	677,535
(Increase) Decrease in prepaid expenses	205	1,494	(1,940)
(Increase) Decrease in inventory	0	(3,602)	0
Increase (Decrease) in accounts payable	109,557	28,774	179,093
Increase (Decrease) in accounts payable - Related party	0	(6,699)	7,628
Increase (Decrease) in accrued liabilities	113,349	87,402	614,255
Increase (Decrease) in accrued liabilities - Related party	276,800	108,194	830,822
Net cash from Continuing Operating Activities	(177,217)	(607,587)	(3,685,170)
Net Cash from Discontinued Operations	0	0	(8,151)
Net Cash from Operating Activities	(177,217)	(607,587)	(3,693,321)
Cash flows from investing activities:
Purchase of intangible assets	(21,170)	(14,875)	(147,440)
Purchase of equipment	0	(6,435)	(218,926)
Net cash from Investing Activities	(21,170)	(21,310)	(366,366)
Cash flows from financing activities:
Issuance of common stock for cash	155,000	249,900	3,151,953
Proceeds from loans payable - Related party	19,818	425,267	909,156
Payments on loans payable - Related Party	0	(15,000)	(25,975)
Net Cash Provided from Continuing Financing Activities	174,818	660,167	4,035,134
Net Cash from Discontinued Operations	0	0	(19,777)
Net Cash from Financing Activities	174,818	660,167	4,015,357
Net increase (decrease) in cash	(23,569)	31,270	(44,330)
Cash at beginning of the period	27,167	28,115	47,928
Cash at end of the period	3,598	59,385	3,598
Supplemental Disclosure Information
Cash paid for interest	0	0	750
Cash paid for Income/Franchise Taxes	0	100	600
Non-cash Financing Activities:
Stock issued for debt and accrued compensation	543,131	0	1,262,948
Stock issued for patents	$ 141,950	$ 0	$ 141,950

GENOSYS, INC. (A Development Stage Company) CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Aug. 31, 2011	Nov. 30, 2010
Cash and cash equivalents	$ 3,598	$ 27,167
Prepaid expenses	2,066	2,271
Total current assets	5,664	29,438
Property and equipment, net of accumulated depreciation and amortization of $185,214 and $162,283, respectively	12,742	35,672
Patents, net of amortization of $49,309 and $32,948, respectively	240,376	93,619
TOTAL ASSETS	258,782	158,729
Accounts payable	179,095	69,538
Accounts payable, Related party	7,628	7,628
Accrued liabilities	425,949	236,142
Accrued liabilities, Related party	412,180	504,969
Loans payable, Related party	227,180	457,363
Total current liabilities	1,252,032	1,275,640
Total liabilities	1,252,032	1,275,640
Common stock, $.001 par value; 100,000,000 shares authorized, 85,965,059 and 62,882,242 shares issued and outstanding at August 31, 2011 and November 30, 2010, respectively	85,965	62,882
Additional paid-in capital	6,254,197	5,284,815
Accumulated deficit	(77,924)	(77,924)
Deficit accumulated in the development stage	(7,255,488)	(6,386,684)
Total stockholders' deficit	(993,250)	(1,116,911)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 258,782	$ 158,729